Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Unknown 4Not yet recruiting 3Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 13Head & Neck 7Tumor-Agnostic 4Dermatologic 3Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Solid Tumor, Adult 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immune Checkpoint Inhibitors × Other solid neoplasm × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡